This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 16 for:    FDG Heterogeneity
Previous Study | Return to List | Next Study

Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study

This study has been completed.
Information provided by (Responsible Party):
Farrokh Dehdashti, Washington University School of Medicine Identifier:
First received: May 20, 2009
Last updated: January 19, 2017
Last verified: January 2017

Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer

The purpose of this study is to evaluate the change in cervical tumor heterogenity as measured by FDG-PET/CT imaging.

Condition Intervention
Cervical Cancer Procedure: Positron Emission Tomography

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Assessment of Changes in Pattern and Magnitude of Tumor FDG Uptake During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer

Resource links provided by NLM:

Further study details as provided by Farrokh Dehdashti, Washington University School of Medicine:

Primary Outcome Measures:
  • The overall goal of this pilot study is to evaluate the change in cervical tumor FDG heterogeneity and SUVmax during chemoradiation. [ Time Frame: FDG PET/CT imaging is performed at: Baseline, 2 & 4 weeks of therapy, and 3 months after completing therapy ]

Secondary Outcome Measures:
  • To correlate changed in FDG heterogeneity and SUVmax with response to therapy. [ Time Frame: 5 years ]

Enrollment: 25
Study Start Date: August 2008
Study Completion Date: December 2016
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Chemoradiation therapy Procedure: Positron Emission Tomography
FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Biopsy-proven cervical cancer. (FIGO stage-Ib2-IVa)
  2. Age ≥ 18
  3. Able to receive chemoradiation therapy with Cisplatin.
  4. Non-pregnant status in women of childbearing potential.
  5. No other active cancer at the time of diagnosis of cervical cancer Patients cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years.
  6. Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least 1 year.
  7. Scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging of cervical cancer at Barnes-Jewish Hospital Clinical PET Facility on a Biograph 40 PET/CT scanner
  8. Able to give informed consent

Exclusion Criteria:

  1. Age < 18
  2. Patients with a known active malignancy other than cervical carcinoma.
  3. Pregnant and breastfeeding patients.
  4. Subjects whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00907140

United States, Missouri
Washington University at St. Louis
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Principal Investigator: Perry W Grigsby, M.D. Washington University at St. Louis
  More Information

Responsible Party: Farrokh Dehdashti, Co-Principal Investigator, Washington University School of Medicine Identifier: NCT00907140     History of Changes
Other Study ID Numbers: 08-0804
Study First Received: May 20, 2009
Last Updated: January 19, 2017

Keywords provided by Farrokh Dehdashti, Washington University School of Medicine:
Cervical Cancer
Positron Emission Tomography

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female processed this record on August 18, 2017